As COVID-19 continually evolves and new therapies are approved and administered individually and in combination, the best way to apply scientific principle is to continue to test each treatment separately and together, beginning with remdesivir.
Remdesivir will only be available at the "government price" to smaller government programs, excluding Medicare and Medicaid. Dr. Peter Bach proposes two options if Gilead wishes to offer the discounts to the full array of government programs.
“Indication-specific pricing” (ISP) is an approach that linking a drug's price to the benefit of the drug in each of its approved indications. The Drug Pricing Lab proposes several approaches that facilitate ISP implementation.
The COVID-19 urgency for vaccine development has popularized a false dichotomy that risk taking that involves forgoing traditional regulatory protocol leads to an expedited timeline for developing effective treatments.
Dr. Peter Bach joins Innovation Hub Radio by WGBH to discuss how incentives provided through policies have rewarded innovation for rare drugs and whether these are the right national healthcare priorities today.
Dr. Peter Bach responds to PhRMA's stance of opposition to H.R. 3 Lower Drug Costs Now Act of 2019. The bill, if passed, would allow Medicare to negotiate drug prices using 120% of international reference price as the payment upper limit.
Together with Mark Trusheim of MIT Sloan School of Management and Preston Atteberry, MD, the Drug Pricing Lab team articulated why biosimilars are not and will not effectively lower the price of biologic drugs after the period of market exclusivity.
Preston J. Atteberry, Peter B. Bach, Jennifer A. Ohn, Mark R. Trusheim